COPD, Tozorakimab, Biologics, Respiratory
Tozorakimab’s Broad COPD Bet Hinges on Biomarker Freedom and Durable Safety
Chronic obstructive pulmonary disease remains a high-burden condition even after optimized inhaled therapy, and the current biologic era has left a large refractory population without a targeted systemic option. Tozorakimab enters that gap with a first-in-class dual IL-33 strategy that aims to expand biologic treatment beyond the eosinophilic restrictions that